Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293239 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTGAATDP1L3MBTL1 | |
| SCHEMBL426569 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTGAATDP1L3MBTL1 | |
| SCHEMBL14340498 | 0.84 | TP53 (0.56) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL8134803 | 0.83 | TP53 (0.57) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL8130639 | 0.82 | TP53 (0.59) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL30293244 | 0.79 | CHRM2 (0.50) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL1289613 | 0.79 | CHRM2 (0.50) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL2095013 | 0.79 | RAB9A (0.58) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL8320072 | 0.79 | RAB9A (0.57) | TP53ALDH1A1MAPTGAATDP1 | |
| SCHEMBL2095011 | 0.79 | RAB9A (0.57) | TP53ALDH1A1MAPTGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609847-B2 | Dihydroquinolinone derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | PER2, CRY1, BACE1 | TP53 3980/4885ALDH1A1 464/4885MAPT 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.